Medicilon Welcomes Dr. Lilly Xu as New Chief Technology Officer to Drive Innovations

Medicilon Appoints Dr. Lilly Xu as New Chief Technology Officer

Medicilon, a leading preclinical research organization (CRO), announced the appointment of Dr. Lilly Xu as its new Chief Technology Officer (CTO) on January 2, 2025. With an impressive career spanning over 30 years in the field of drug research, Dr. Xu is set to spearhead the technological advancements and global outreach of Medicilon, reinforcing its commitment to delivering groundbreaking research and development solutions.

Dr. Xu, who earned her PhD in biology from the University of St. Louis, has built a reputation as a recognized expert in pharmacokinetics, toxicology, and drug metabolism. Her extensive experience includes overseeing numerous global drug development programs from early stages to clinical trials, having held leadership roles in major pharmaceutical and biotechnology companies such as Pharmaron, Icagen, Purdue Pharma, Sanofi, and Amgen.

"We are thrilled to have Dr. Xu join our team at this pivotal moment for Medicilon's growth," said Dr. Chunlin Chen, founder and CEO of Medicilon. "Her vast experience and global perspective align perfectly with our vision for innovation and expanding our international reach."

In her new role, Dr. Xu expressed her excitement and commitment to the team, stating, “It is an honor for me to join the talented team at Medicilon. I look forward to contributing to platform innovations that will accelerate the transition from scientific research to clinical breakthroughs, achieving milestones that will benefit our global clients and their patients.”

Medicilon continues to enhance its advanced research platforms, including studies on nucleic acids, antibody-drug conjugates (ADC), PROTAC technology, antibodies, cell and gene therapies, solidifying its position as a leader in preclinical drug research. This strategic appointment highlights the company's dedication to innovation, aiming to provide cutting-edge solutions in the biopharmaceutical field.

For further information about Medicilon and its research initiatives, visit Medicilon’s official website.

Dr. Lilly Xu